Latest news

Filter by category:

FILTER: ALL CATEGORIESFilter by:

Latest news

24 Nov 2020

Ensuring safety of COVID-19 vaccines
Dr Robert Chen, leading vaccine-safety expert, discusses the importance of safety monitoring for COVID-19 vaccines

Read more

Read article

24 Nov 2020

Indonesia donates US $1 million to further CEPI’s vaccine research and combat epidemic threats
The financial contribution will further vaccine programmes against CEPI's target diseases.

Read more

23 Nov 2020

CEPI welcomes University of Oxford / AstraZeneca encouraging interim COVID-19 vaccine efficacy data
"It is terrific to see another approach to vaccine development also yielding such positive findings on an interim analysis," says CEPI CEO, Richard Hatchett.

Read more

18 Nov 2020

CEPI creates new collaborative taskforce to assess impact of emerging viral strains on effectiveness of COVID-19 vaccines
CEPI and partners will work to further strengthen real-time global tracking and testing of SARS-CoV-2 sequences.

Read more

16 Nov 2020

CEPI welcomes Moderna announcement of positive interim data from Phase III trial of COVID-19 vaccine candidate
The announcement provides further confirmation that spike-directed COVID-19 vaccine candidates can provide a strong protective immune response.

Read more

12 Nov 2020

CEPI receives funding for development of ‘next generation’ of COVID-19 vaccine candidates
New grant will accelerate vaccine candidates with different characteristics to those already in development.

Read more

11 Nov 2020

CEPI welcomes launch of new Plague Inc. game to show the world how to stop the next pandemic
With scientific input from infectious disease experts, including CEPI, Plague Inc: The Cure shows one of the most detailed and interactive representations of a pandemic.

Read more

09 Nov 2020

CEPI welcomes announcement from Pfizer / BioNTech of positive interim data from Phase III trial of COVID-19 vaccine candidate

Read more

Read article

03 Nov 2020

CEPI extends partnership with Clover to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure
The expanded partnership is a result of Clover’s successful early stage clinical development of the S-Trimer vaccine candidate.

Read more

30 Oct 2020

COVAX welcomes appointment of civil society representatives
Those selected will provide valuable technical expertise and use their experiences in a number of key COVAX groups working to ensure equitable access to COVID-19 vaccines.

Read more

28 Oct 2020

Italy pledges first EUR 5 million funding to CEPI to advance COVID-19 vaccine development efforts
Financial contribution is part of a larger donation to support CEPI's work.

Read more

©2020 CEPI. All rights reserved

This website uses cookies to improve functionality and performance. If you continue browsing the site, you consent to the use of cookies on this website. For details, see our Cookie Notice.